Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL106624 | 0.84 | LPL (0.31) | LPLLIPG | |
| SCHEMBL8737458 | 0.75 | LPL (0.36) | LPLLIPG | |
| SCHEMBL24457824 | 0.71 | LPL (0.36) | LPLLIPG | |
| SCHEMBL1180717 | 0.70 | DGAT1 (0.42) | LPLLIPG | |
| SCHEMBL8049652 | 0.70 | MAPK1 (0.30) | — | |
| SCHEMBL31380588 | 0.69 | LPL (0.46) | LPLLIPG | |
| SCHEMBL168780 | 0.69 | LPL (0.46) | LPLLIPG | |
| SCHEMBL1315596 | 0.68 | MAPK1 (0.44) | — | |
| SCHEMBL106003 | 0.67 | TDP1 (0.35) | — | |
| SCHEMBL190545 | 0.67 | LPL (0.40) | LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9233111-B2 | Pyrrolo pyrimidine derivatives | NOVARTIS AG (CH) | 2016-01-12 | — | — | US | disclosed |
| EP-2729466-B1 | NOVEL PYRROLO PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2015-08-19 | — | — | EP | disclosed |
| US-20140243306-A1 | NOVEL PYRROLO PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2014-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243306-A1 | NOVEL PYRROLO PYRIMIDINE DERIVATIVES | BTK, LCK, ZAP70 | LPL 4613/4885LIPG 4262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.